Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5282114 | 1.00 | HDAC1 (0.46) | HDAC1HDAC2DPP4HDAC3PRCP | |
| SCHEMBL5281811 | 0.86 | ITGB1 (0.47) | DPP4PRCPITGB1ITGA4ALDH1A1 | |
| SCHEMBL5281806 | 0.86 | ITGB1 (0.47) | DPP4PRCPITGB1ITGA4ALDH1A1 | |
| SCHEMBL5353477 | 0.84 | DPP4 (0.51) | DPP4PRCPALDH1A1 | |
| SCHEMBL5353470 | 0.84 | DPP4 (0.51) | DPP4PRCPALDH1A1 | |
| SCHEMBL5280371 | 0.83 | ALDH1A1 (0.54) | DPP4PRCPITGB1ITGA4ALDH1A1 | |
| SCHEMBL5280364 | 0.83 | ALDH1A1 (0.54) | DPP4PRCPITGB1ITGA4ALDH1A1 | |
| SCHEMBL5281177 | 0.83 | DPP4 (0.49) | DPP4PRCPALDH1A1 | |
| SCHEMBL5281181 | 0.83 | DPP4 (0.49) | DPP4PRCPALDH1A1 | |
| SCHEMBL5277535 | 0.80 | TSHR (0.50) | DPP4PRCPALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC2 5/4885DPP4 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.